QTREX Quantum Ltd 6-K, filed Nov 29, 2023
QTREX Quantum Ltd. (QTEX)
About this 6-K
QTREX Quantum Ltd filed this 6-K on November 29, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2023 (Report No. 5)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On November 29, 2023, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Inspira Collaborates with Ennocure for Development of Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.
The Report on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (Registration No. 333-266748) and Form S-8 (Registration No. 333-259057), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Inspira Technologies Oxy B.H.N. Ltd. | |||
| Date: November 29, 2023 | By: | /s/ Dagi Ben-Noon | |
| Name: | Dagi Ben-Noon | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
Inspira Collaborates with Ennocure for Development of Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients
Ra’anana, Israel, November 29, 2023 – Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira”), an innovator in life support technology, is excited to announce a partnership with Ennocure MedTech Ltd. (“Ennocure”).
At the core of Inspira’s mission is a groundbreaking approach to oxygenate blood directly to replace life support mechanical ventilation. Inspira seeks to include bio-electronic technology as part of the INSPIRA ART and Company’s IP portfolio, to prevent the growth of bacteria that often results in a bloodstream infection (sepsis) and has partnered with Ennocure for the development of such treatment.
Today, it is estimated that 250,000 bloodstream infections related to intravenous lines occur worldwide each year, leading to prolonged hospital stays and increasing healthcare costs.
Once developed, Inspira plans to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce complications.
Dagi-Ben Noon, CEO of Inspira, reflects on the partnership’s significance: “By Integrating our technology to oxygenate blood directly with Ennocure’s infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology.”
About Ennocure MedTech Ltd.
Ennocure is a pioneer in the development of bioelectronic wound dressing. At the core of the technology is a proprietary bioelectronic wound dressing designed to prevent bacterial infections, while providing remote wound monitoring & infection alerts based on AI-driven personalized therapy.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is leading the way in transforming life-support care. Its innovative solutions are paving the way for direct blood oxygenation, bypassing the lungs, and potentially reducing the need for traditional mechanical ventilation. Beyond this, the Company is committed to advancing blood circulation technology and incorporating AI-driven monitoring systems. These advancements are part of its strategy to offer more patient-focused, data-informed care. The integration of these technologies signifies the potential to enhance patient outcomes and streamline hospital operations, marking a new era in respiratory care.
For more information, please visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the partnership with Ennocure for the development of a bio-electronic treatment to prevent associated bloodstream infections in ICU patients, when it discusses the benefits of the treatment and the integration of Ennocure’s technology, when it discusses Inspira’s plans to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce complications, or when it discusses that this collaboration is expected to accelerate the development and broaden the implementation of Inspira’s technology. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2022 filed with the SEC, which is available on the SEC’s website, www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
MRK-ARS-074
Copyright © 2018-2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved. MRK-ARS-077